March 25, 2024
The first biosimilar version of the age-related macular degeneration treatment Eylea (aflibercept) might be nearing the finish line in the regulatory review in Japan, with its Japanese non-proprietary name, or JAN, now determined. On March 22, the Ministry of Health,...read more